Cftr Trikafta denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Flags Trikafta as Duplicate Therapy

Aetna may issue a duplicate-therapy denial when its utilization-management system detects another CFTR modulator—or a medication it categorizes in the same therapeutic class—already active on your profile. This can happen during a transition between modulators, when a prior prescription has not yet been closed out in the claims system, or when a combination regimen is misread as overlapping single agents.

This type of denial is routinely overturned on appeal because the clinical record almost always shows a clear, documented reason for the regimen: a mutation profile that matches Trikafta's approved indication, a prior modulator that was discontinued (with dates and reasons), and a prescriber judgment that the specific combination is medically necessary and non-redundant.

## Your Federal Appeal Rights

Regardless of whether your plan is fully insured or self-funded, you have structured appeal rights:

• Internal appeal (Level 1): Must be filed within the timeframe shown on your denial letter (typically 180 days). The plan must decide within 30 days for pre-service or 60 days for post-service claims.
• External review (ACA §2719 / state law): After exhausting internal appeals—or if the plan misses its deadline—you may request independent external review. The reviewer is a neutral, accredited organization. The window to request external review is generally 4 months from the date of the final internal denial.
• ERISA §503 (self-funded plans): Guarantees a full-and-fair review with access to the clinical criteria used. You are entitled to a copy of all documents, records, and guidelines relied upon.
• Expedited review: If waiting for standard review timelines would seriously jeopardize your health, request expedited internal and external review simultaneously.

## Documentation to Gather

1. Diagnosis confirmation: Genetic mutation report confirming the CF genotype; current pulmonary function and clinical status notes. 2. Medication history: Complete list of all prior CFTR modulators with start dates, stop dates, and documented reasons for discontinuation. 3. Active prescription reconciliation: Confirmation from the dispensing pharmacy that no other CFTR modulator is currently being filled—eliminating the factual basis for the duplicate claim. 4. Prescriber letter: A signed medical-necessity letter explaining why Trikafta is the appropriate agent for this patient's specific mutation, why prior agents were stopped, and why the regimen is not duplicative. 5. Plan policy: Download Aetna's current published clinical policy for CFTR modulators. Map each criterion to the specific chart documentation that satisfies it.

## Criteria-Mapping Structure

When you write your appeal, build a table:

| Policy Requirement (copy exact text from Aetna's policy) | Supporting Chart Evidence | |---|---| | Eligible CF genotype | Genetic report dated __ | | No concurrent CFTR modulator | Pharmacy reconciliation letter dated __ | | Prescriber attestation of non-redundancy | Dr. ___ letter dated __ |

Address the duplicate-therapy finding head-on: state the specific prior drug, its stop date, and the clinical reason it was discontinued. A clear discontinuation narrative removes the premise of the denial.